Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (632)	4/9/1998 12:22:00 AM
From: Vector1	Read Replies (1) \| Respond to of 1686

Harold, thanks for the excellent summary. Looked like Avonex sales continued to be robust. Was there any discussion of Avonex's growth in Europe. Also royalties were down about $4m year over year for the quarter. Last year they were still signaling double digit growth and Intron A has been strong. I am looking forward to reading the transcript and we will see what the street thinks of the numbers tomorrow. V1